9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more

Genomas, Inc.
67 Jefferson Street
Hartford, CT 06106

Phone: 860 545 4574
Fax: 860 545 4575
Website: http://genomas.net/

Gualberto Ruaño, President & CEO

General Information
Genomas is a biomedical company advancing personalized health with revolutionary PhyzioTypeTM systems for DNA-guided diagnosis and prevention of serious side effects induced by cardiovascular, psychiatric, and diabetic medications. The products are being developed in partnership with three leading CT medical institutions, Hartford Hospital, The Institute of Living and The Hospital of Central Connecticut.

PhyzioTypeTM medical management systems will change the current course of treatment. They provide physicians the unprecedented capability to prevent serious side effects based on the patient?s DNA. By comparing side effect risks of drugs in a therapeutic class for each patient and by forewarning doctors of adverse responses that will complicate treatment, PhyzioTypeTM systems eliminate trial and error with DNA- guided medicine. A PhyzioTypeTM system has 3 proprietary components: an ensemble of inherited, stable DNA markers from several genes, a biostatistical algorithm validated in clinical studies for ascertaining the clinical significance of a patient?s DNA marker configuration, and a graphical portal for doctors to select drugs based on an individual?s risk of developing side effects.